Publications by authors named "M Vignetti"
Given the limited data on the real-life therapeutic use of feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3) inhibitors in Italy, we surveyed investigators at 59 Italian hematology centers to gain insight into the proportion of acute myeloid leukemia (AML) patients receiving FLT3 inhibitors and we collected data on the efficacy and safety of these agents. The survey results showed that in the real-life setting the response rate of the 3/7 + midostaurin regimen in newly diagnosed FLT3-mutated AML and of gilteritinib in the relapsed/refractory AML were comparable to that reported in the registrative clinical trials. The 3/7 + midostaurin treatment resulted in a 63% of complete remission (CR) rates and gilteritinib in a 44% of CR rates.
View Article and Find Full Text PDFArticle Synopsis
- Treatment outcomes for acute promyelocytic leukemia (APL) have significantly improved through targeted therapies like ATRA and arsenic trioxide, as confirmed by a study analyzing 1,438 newly diagnosed patients from 1999 to 2022.
- Among those treated, patients receiving the ATRA-ATO regimen demonstrated a higher 7-year overall survival rate (91%) compared to those on AIDA-like chemotherapy (81%), along with better event-free survival and lower relapse rates.
- The study highlights the ongoing issue of early death, particularly in older patients and those with high Sanz risk scores, suggesting a need for further examination and targeted interventions in these vulnerable groups.
Article Synopsis
- * After a median follow-up of 10 years, 117 patients were assessed, with half receiving ATO and half receiving chemotherapy.
- * Results showed that ATO treatment was associated with significantly better cognitive function and lower fatigue, indicating sustained HRQoL benefits compared to chemotherapy over the long term.
Article Synopsis
- In the past decade, targeted kidney inhibitors (TKIs) have significantly improved the survival rates of chronic myeloid leukemia (CML) patients, particularly those achieving deep and sustained molecular response (DMR), allowing some to consider stopping treatment.
- A study analyzed responses from 1,777 CML patients in Italy, focusing on the impact of different TKIs (imatinib, dasatinib, nilotinib) and timing of responses (3, 6, and 12 months).
- Results showed that patients achieving certain molecular response benchmarks at 3 months were more likely to achieve DMR later, with significant differences in outcomes based on the specific TKI used.
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.
Haematologica
January 2025
The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL) has significantly improved patients' prognosis. Within the Campus ALL network, we analyzed the outcome of adult Ph- ALL patients treated according to the GIMEMA LAL1913 protocol outside the clinical trial to compare the real-life data with the study results. We included 421 consecutive patients; median age 42 years.
View Article and Find Full Text PDF